Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance.
Thomas EbertStefan D AnkerLuis M RuilopePaola FiorettoVivian A FonsecaGuillermo E UmpierrezAndreas L BirkenfeldRobert LawatscheckCharlie ScottKatja RohwedderEllen Burgessnull nullPublished in: Diabetes care (2024)
Insulin resistance was associated with increased cardiovascular (but not kidney) risk and did not modify finerenone efficacy.